Validation of Novel Metabolic, Inflammatory, and Hepatic-Renal Biomarkers-HbA1c/C-peptide Ratio, Neutrophil/HDL Ratio, and ALBI Score-for Predicting the No-Reflow Phenomenon After Primary PCI in Patients With STEMI.
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 114
- 主要终点
- HbA1c/C-peptide ratio predictive accuracy for no-reflow phenomenon
研究概览
简要总结
To evaluate the diagnostic value of the selected emerging biomarkers in predicting the no-reflow phenomenon among patients presenting with STEMI undergoing primary PCI. These biomarkers include:
HbA1c/C-peptide ratio
Albumin-bilirubin (ALBI) score.
Neutrophil/HDL ratio
详细描述
The no-reflow phenomenon is a well-recognized complication following primary percutaneous coronary intervention (PCI) in patients presenting with ST-segment elevation myocardial infarction (STEMI). Despite successful opening of the occluded coronary artery, impaired myocardial perfusion may persist, significantly increasing the risk of adverse cardiovascular outcomes.
Recent research has identified several novel biomarkers that may help predict the risk of no-reflow. These include metabolic, inflammatory, and hepatic-renal markers that reflect the systemic milieu of patients with acute coronary syndromes. Among these emerging biomarkers, the following are of particular interest:
- HbA1c/C-peptide ratio: Reflects chronic glycemic burden and residual beta-cell function.
- Neutrophil/HDL ratio: A combined marker of inflammation and lipid-associated atheroprotection.
- Albumin-bilirubin (ALBI) score: A composite liver function marker potentially linked to systemic inflammation and perfusion status.
This study aims to validate the prognostic value of these biomarkers in predicting the no-reflow phenomenon in STEMI patients undergoing primary PCI.
To validate the clinical utility of selected emerging biomarkers in predicting the no-reflow phenomenon among patients presenting with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years
- •Suitable for and undergoing timely primary PCI based on symptoms and clinical judgment
- •Provision of informed consent
排除标准
- •History of previous MI, PCI, or CABG
- •Known chronic inflammatory or autoimmune diseases
- •Advanced renal or hepatic failure
- •Active infection or malignancy at presentation
- •Incomplete data or refusal to consent
结局指标
主要结局
HbA1c/C-peptide ratio predictive accuracy for no-reflow phenomenon
时间窗: Baseline (prior to PCI)
Diagnostic accuracy of HbA1c/C-peptide ratio for predicting the no-reflow phenomenon in STEMI patients undergoing primary PCI, assessed by area under the ROC curve (AUC).
Neutrophil/HDL ratio predictive accuracy for no-reflow phenomenon
时间窗: Baseline (prior to PCI)
Diagnostic accuracy of neutrophil/HDL ratio for predicting the no-reflow phenomenon in STEMI patients undergoing primary PCI, assessed by area under the ROC curve (AUC).
Albumin-bilirubin (ALBI) score predictive accuracy for no-reflow phenomenon
时间窗: Baseline (prior to PCI)
Diagnostic accuracy of ALBI score for predicting the no-reflow phenomenon in STEMI patients undergoing primary PCI, assessed by area under the ROC curve (AUC).
次要结局
- Correlation of HbA1c/C-peptide ratio, Neutrophil-to-HDL ratio, and Albumin-Bilirubin (ALBI) score with in-hospital major adverse cardiovascular events (MACE).(Baseline to hospital discharge.)
- Correlation of HbA1c/C-peptide ratio, Neutrophil-to-HDL ratio, and Albumin-Bilirubin (ALBI) score with 1-month major adverse cardiovascular events (MACE).(Baseline to 1-month follow-up.)
研究者
Hossam Eldin Alaa Abdelhafiz mohamed
Principal investigator, cardiology Department
Assiut University